Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation

Transplantation Proceedings

Volumn 28, Issue 2, 1996, Pages 913-914

  Kovarik, J M ^a   Rawlings, E ^a   Sweny, P ^a   Fernando, O ^a   Moore, R ^a   Griffin, P J ^a   Fauchald, P ^a   Albrechtsen, D ^a   Sodal, G ^a   Nordal, K ^a   Amlot, P L ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BINDING AFFINITY; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; MALE; MICE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0029936659     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)